{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:08:17Z","timestamp":1793326097142,"version":"4.5.0"},"reference-count":135,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.jaad.2013.05.002","type":"journal-article","created":{"date-parts":[[2013,7,15]],"date-time":"2013-07-15T23:13:50Z","timestamp":1373930030000},"page":"187.e1-187.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":263,"title":["Toxic epidermal necrolysis"],"prefix":"10.1016","volume":"69","author":[{"given":"Robert A.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H.","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2013.05.002_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens\u2013Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaad.2013.05.002_bib2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2230.2010.03826.x","article-title":"Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre","volume":"35","author":"Rajaratnam","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity of illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib5","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archderm.140.7.890","article-title":"Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States","volume":"140","author":"Trent","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/BCR.0b013e31815f3865","article-title":"SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center","volume":"29","author":"Cartotto","year":"2008","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.jaad.2013.05.002_bib7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Gu\u00e9gan","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib8","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1365-2133.2007.08222.x","article-title":"Respiratory involvement in toxic epidermal necrolysis portends a poor prognosis that may not be reflected in SCORTEN","volume":"157","author":"Hague","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.bcr.0000194268.01514.f8","article-title":"Long term follow-up of patients treated for toxic epidermal necrolysis","volume":"27","author":"Oplatek","year":"2006","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.jaad.2013.05.002_bib10","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jaad.2011.10.007","article-title":"Prognostic value of histologic features of toxic epidermal necrolysis","volume":"68","author":"Valeyrie-Allanore","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/0885066610390466","article-title":"Serum bicarbonate as a marker to predict mortality in toxic epidermal necrolysis","volume":"26","author":"Yeong","year":"2011","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.jaad.2013.05.002_bib12","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/01.PRS.0000019761.69444.10","article-title":"Outcome of patients with toxic epidermal necrolysis syndrome revisited","volume":"110","author":"Ducic","year":"2002","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jaad.2013.05.002_bib13","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis: clinical findings and prognostic factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib14","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0190-9622(85)70207-1","article-title":"Acute disseminated epidermal necrolysis types 1,2 and 3: study of 60 cases","volume":"13","author":"Ruiz-Maldonado","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0190-9622(91)70176-3","article-title":"Toxic epidermal necrolysis: a review","volume":"25","author":"Avakian","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib16","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/archderm.1978.01640210079034","article-title":"Eruptive nevocytic nevi after Lyell\u2019s syndrome","volume":"114","author":"Goerz","year":"1978","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib17","first-page":"153","article-title":"Vulvovaginal sequelae in toxic epidermal necrolysis","volume":"42","author":"Meneux","year":"1997","journal-title":"J Reprod Med"},{"key":"10.1016\/j.jaad.2013.05.002_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0029-7844(97)00596-6","article-title":"Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases","volume":"91","author":"Meneux","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jaad.2013.05.002_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1542\/peds.109.1.74","article-title":"Long-term consequences of toxic epidermal necrolysis in children","volume":"109","author":"Sheridan","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2013.05.002_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.BCR.0000150215.78220.79","article-title":"Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center","volume":"26","author":"Haber","year":"2005","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2013.05.002_bib21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0733-8635(18)30324-3","article-title":"Oculocutaneous manifestations of the erythema multiforme\/Stevens-Johnson syndrome\/toxic epidermal necrolysis spectrum","volume":"10","author":"Wilkins","year":"1992","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2013.05.002_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000070938","article-title":"Dermatological and ophthalmological sequels in toxic epidermal necrolysis","volume":"207","author":"Magina","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2013.05.002_bib23","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ophtha.2004.11.035","article-title":"Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Jonson syndrome and toxic epidermal necrolysis syndrome","volume":"112","author":"Di Pascuale","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaad.2013.05.002_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/0019-5154.77546","article-title":"Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis over a period of 10 years","volume":"56","author":"Sanmarkan","year":"2011","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/00015550510038232","article-title":"Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients","volume":"85","author":"Kim","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2013.05.002_bib26","first-page":"157","article-title":"Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"145","author":"Gueudry","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/07853890701753664","article-title":"Stevens-Johnson syndrome: pathogenesis diagnosis, and management","volume":"40","author":"Hazin","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.jaad.2013.05.002_bib28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jaad.2011.09.029","article-title":"Toxic epidermal necrolysis: review of pathogenesis and management","volume":"66","author":"Downey","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib29","first-page":"5","article-title":"Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome","volume":"8","author":"Ghislain","year":"2002","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2013.05.002_bib30","series-title":"Nelson textbook of pediatrics","first-page":"2214.e2","article-title":"Evaluation of the patient","author":"Morelli","year":"2011"},{"key":"10.1016\/j.jaad.2013.05.002_bib31","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/archdermatol.2009.233","article-title":"Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis","volume":"145","author":"Gaultier","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0378-6323.110749","article-title":"A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population","volume":"79","author":"Patel","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2013.05.002_bib33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00004630-199605000-00009","article-title":"Acute and chronic respiratory complications of toxic epidermal necrolysis","volume":"17","author":"McIvor","year":"1996","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2013.05.002_bib34","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1346-8138.2006.00142.x","article-title":"Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti-Ro\/SS-A and a review of the published work","volume":"33","author":"Kamada","year":"2006","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib35","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.tripleo.2007.12.023","article-title":"Toxic epidermal necrolysis with a rare long-term oral complication requiring surgical intervention","volume":"105","author":"Sedghizadeh","year":"2008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.jaad.2013.05.002_bib36","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1542\/peds.89.3.429","article-title":"Unusual manifestation of Stevens-Johnson syndrome involving the respiratory and gastrointestinal tract","volume":"89","author":"Edell","year":"1992","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2013.05.002_bib37","first-page":"5","article-title":"A clinicoetiological study of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"23","author":"Gardezi","year":"2013","journal-title":"J Parkistan Assoc Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib38","first-page":"123","article-title":"Toxic epidermal necrolysis","volume":"59","author":"Schwartz","year":"1997","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2013.05.002_bib39","series-title":"Dermatology","first-page":"323","article-title":"Toxic epidermal necrolysis","author":"French","year":"2003"},{"key":"10.1016\/j.jaad.2013.05.002_bib40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archderm.1995.01690170041005","article-title":"Erythema multiforme with mucous-membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes","volume":"131","author":"Assier","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib41","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib42","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1684\/ejd.2011.1510","article-title":"Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)\/toxic epidermal necrolysis (TEN)","volume":"21","author":"Watanabe","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib43","first-page":"7","article-title":"The erythema multiforme spectrum: pathogenesis, pathology and links with the pemphigus spectrum","volume":"15","author":"Schwartz","year":"1998","journal-title":"Postepy Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib44","first-page":"6","article-title":"Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"135","author":"Rzany","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib45","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jaad.2008.09.015","article-title":"Cutaneous drug eruptions: a 5-year experience","volume":"59","author":"Gerson","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1346-8138.2009.00746.x","article-title":"Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen section diagnosis","volume":"37","author":"Hosaka","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib47","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaci.2008.06.013","article-title":"Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment","volume":"122","author":"Murata","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2013.05.002_bib48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2013.05.002_bib49","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/j.1365-2133.2006.07211.x","article-title":"Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis spectrum","volume":"154","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib50","doi-asserted-by":"crossref","first-page":"514","DOI":"10.7326\/0003-4819-151-7-200910060-00016","article-title":"Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome","volume":"151","author":"Abe","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2013.05.002_bib51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jaad.2010.04.042","article-title":"Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"65","author":"Fujita","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib52","unstructured":"Callen JP. On the horizon: test to predict Stevens-Johnson syndrome\/toxic epidermal necrolysis. Journal Watch. Available at: http:\/\/dermatology.jwatch.org. Accessed August 30, 2012."},{"key":"10.1016\/j.jaad.2013.05.002_bib53","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/archdermatol.2011.239","article-title":"High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"147","author":"Nakajima","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib54","unstructured":"Innovation Beyond Limits International. HMGB1 ELISA 2012. Available at: http:\/\/www.ibl-international.com. Accessed August 30, 2012."},{"key":"10.1016\/j.jaad.2013.05.002_bib55","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/0885066612465259","article-title":"Emerging new markers of toxic epidermal necrolysis","volume":"28","author":"Kapoor","year":"2013","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.jaad.2013.05.002_bib56","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1398-9995.2010.02484.x","article-title":"Expression of alpha-defensin 1-3 in T cells from severe cutaneous drug-induced hypersensitivity reactions","volume":"66","author":"Morel","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2013.05.002_bib57","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/039463200702000313","article-title":"Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"20","author":"Marzano","year":"2007","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jaad.2013.05.002_bib58","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000148255","article-title":"Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in the early stage of toxic epidermal necrolysis","volume":"217","author":"Yun","year":"2008","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2013.05.002_bib59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000097652","article-title":"Glutathione-s-transferase pi expression in toxic epidermal necrolysis: a marker of putative oxidative stress in keratinocytes","volume":"20","author":"Paquet","year":"2007","journal-title":"Skin Pharmacol Physiol"},{"key":"10.1016\/j.jaad.2013.05.002_bib60","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-4632.2011.05348.x","article-title":"Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatology","volume":"51","author":"Sokumbi","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib61","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1128\/JCM.43.4.1890-1893.2005","article-title":"Clinical manifestations of staphylococcal scalded skin syndrome depend on serotypes of exfoliative toxins","volume":"43","author":"Yamasaki","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jaad.2013.05.002_bib62","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.0022-202X.2005.23642.x","article-title":"Epidemiology of staphylococcal scalded skin syndrome in Germany","volume":"124","author":"Mockenhaupt","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib63","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaad.2006.04.048","article-title":"Toxic epidermal necrolysis","volume":"56","author":"Pereira","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib64","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1346-8138.1990.tb01689.x","article-title":"Action of staphylococcal exfoliative toxins on epidermal cell cultures and organotypic skin","volume":"17","author":"Gentilhomme","year":"1990","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib65","first-page":"65","article-title":"Vancomycin-induced linear IgA bullous dermatosis: morphology is a key to diagnosis","volume":"73","author":"Solky","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2013.05.002_bib66","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1346-8138.2005.tb00839.x","article-title":"Drug-induced linear IgA bullous dermatosis","volume":"32","author":"Onodera","year":"2005","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib67","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0738-081X(93)90161-5","article-title":"Drug-induced linear immunoglobulin A disease","volume":"11","author":"Collier","year":"1993","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib68","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2009.03.026","article-title":"Drug-induced linear IgA bullous dermatosis demonstrating the isomorphic phenomenon","volume":"62","author":"McDonald","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib69","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0738-081X(98)00009-1","article-title":"Drug-induced linear immunoglobulin-A bullous dermatosis","volume":"16","author":"Camilleri","year":"1998","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib70","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2230.2008.03011.x","article-title":"Drug-associated linear IgA disease mimicking toxic epidermal necrolysis","volume":"34","author":"Khan","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"5 suppl","key":"10.1016\/j.jaad.2013.05.002_bib71","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1067\/mjd.2003.116","article-title":"Vancomycin-associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis","volume":"48","author":"Dellavalle","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib72","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1529-8019.2011.01397.x","article-title":"Cutaneous graft-versus-host disease: rationales and treatment options","volume":"24","author":"Chavan","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2013.05.002_bib73","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","article-title":"Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern","volume":"28","author":"Sidoroff","year":"2001","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2013.05.002_bib74","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jaad.2013.01.032","article-title":"DRESS syndrome: Part I. Clinical perspectives","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib75","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2013.05.002_bib76","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(00)03137-8","article-title":"Idiosyncratic drug reactions: the reactive metabolite syndromes","volume":"356","author":"Knowles","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2013.05.002_bib77","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.iac.2004.03.011","article-title":"Sulfonamide hypersensitivity","volume":"24","author":"Slatore","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaad.2013.05.002_bib78","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2013.05.002_bib79","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1097\/00003246-200211000-00029","article-title":"Recurrent fatal drug- induced toxic epidermal necrolysis (Lyell\u2019s syndrome) after putative beta-lactam cross-reactivity: case report and scrutiny of antibiotic imputability","volume":"30","author":"Paquet","year":"2002","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jaad.2013.05.002_bib80","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.05.002_bib81","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.05.002_bib82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2133.2011.10759.x","article-title":"Response 1 to pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal","volume":"166","author":"Shen","year":"2012","journal-title":"Br Assoc Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib83","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaad.2013.05.002_bib84","unstructured":"US Food and Drug Administration website. Information for healthcare professionals: dangerous or even fatal skin reactions\u2013carbamazepine. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketdrugsafetyinformationforPatientsandProviders\/ucm124718.htm. Accessed August 30, 2012."},{"key":"10.1016\/j.jaad.2013.05.002_bib85","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2133.2011.10754.x","article-title":"Pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal","volume":"166","author":"Wu","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib86","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1398-9995.2007.01553.x","article-title":"Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption","volume":"62","author":"Kano","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2013.05.002_bib87","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2222.2011.03875.x","article-title":"Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"42","author":"Tang","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaad.2013.05.002_bib88","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.autrev.2008.06.004","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Borchers","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2013.05.002_bib89","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/00006534-199809020-00014","article-title":"Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to a regional burn center","volume":"102","author":"McGee","year":"1998","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jaad.2013.05.002_bib90","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2013.05.002_bib91","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.burns.2007.06.008","article-title":"Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilization and decreases infection in elderly patients","volume":"34","author":"Boorboor","year":"2008","journal-title":"Burns"},{"key":"10.1016\/j.jaad.2013.05.002_bib92","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1468-3083.2012.04572.x","article-title":"Umbilical cord mesenchymal stem cell transplantation in drug-induced Stevens-Johnson syndrome","volume":"27","author":"Li","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.05.002_bib93","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1468-3083.2012.04667.x","article-title":"Toxic epidermal necrolysis with failure of re-epithelialization. Could umbilical cord mesenchymal stem cell transplantation have a role?","volume":"27","author":"Lehloenya","year":"2013","journal-title":"J Euro Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.05.002_bib94","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1468-3083.2012.04666.x","article-title":"Answer to \u2018Toxic epidermal necrolysis with failure of re-epithelialization. Could umbilical cord mesenchymal stem cell transplantation have a role?\u2019","volume":"27","author":"Li","year":"2013","journal-title":"J Euro Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.05.002_bib95","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.burns.2006.12.008","article-title":"Aquacel Ag in the treatment of toxic epidermal necrolysis (TEN)","volume":"34","author":"Huang","year":"2008","journal-title":"Burns"},{"key":"10.1016\/j.jaad.2013.05.002_bib96","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.ophtha.2011.01.046","article-title":"Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases","volume":"118","author":"Gregory","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaad.2013.05.002_bib97","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ajo.2009.07.006","article-title":"Vision-related function after scleral lens fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"148","author":"Tougeron-Brousseau","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaad.2013.05.002_bib98","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jaad.2013.05.002_bib99","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1468-3083.2011.04143.x","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998-2008","volume":"26","author":"Zajicek","year":"2012","journal-title":"J Euro Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.05.002_bib100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib101","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib102","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-4632.2004.02048.x","article-title":"Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis","volume":"43","author":"Al-Mutairi","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib103","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000051702","article-title":"Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience","volume":"203","author":"Stella","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2013.05.002_bib104","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4103\/0378-6323.18943","article-title":"Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study","volume":"71","author":"Mangla","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2013.05.002_bib105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2013.05.002_bib106","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2013.05.002_bib107","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib108","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib109","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jaad.2008.07.004","article-title":"The EuroSCAR study: cannot agree with the conclusions","volume":"59","author":"Pehr","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib110","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.burns.2006.08.014","article-title":"Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis","volume":"33","author":"Stella","year":"2007","journal-title":"Burns"},{"key":"10.1016\/j.jaad.2013.05.002_bib111","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-4632.2009.04166.x","article-title":"Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China","volume":"48","author":"Yang","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib112","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1529-8019.2011.01396.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options","volume":"24","author":"Workswick","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2013.05.002_bib113","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systemic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib114","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"10.1016\/j.jaad.2013.05.002_bib115","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2013.05.002_bib116","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/CCM.0b013e31821201ed","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review","volume":"139","author":"Gerull","year":"2011","journal-title":"Critical Care Med"},{"key":"10.1016\/j.jaad.2013.05.002_bib117","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1097\/BCR.0b013e318254d2ec","article-title":"Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China","volume":"33","author":"Zhu","year":"2012","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.jaad.2013.05.002_bib118","first-page":"915314","article-title":"Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: successful treatment of an elderly patient","volume":"2012","author":"Patmanidis","year":"2012","journal-title":"Case Rep Dermatol Med"},{"key":"10.1016\/j.jaad.2013.05.002_bib119","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1346-8138.2010.01154.x","article-title":"Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy?","volume":"38","author":"Narita","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-4362.1997.00192.x","article-title":"Plasmapheresis in toxic epidermal necrolysis","volume":"36","author":"Chaidemenos","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib121","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1526-0968.2002.00409.x","article-title":"Plasma exchange in patients with toxic epidermal necrolysis","volume":"6","author":"Bamichas","year":"2002","journal-title":"Ther Apher"},{"key":"10.1016\/j.jaad.2013.05.002_bib122","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.1998.tb00094.x","article-title":"A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis","volume":"2","author":"Yamada","year":"1998","journal-title":"Ther Apher"},{"key":"10.1016\/j.jaad.2013.05.002_bib123","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(99)70497-4","article-title":"Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis","volume":"40","author":"Egan","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib124","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jca.21213","article-title":"Beneficial effects of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases","volume":"27","author":"Kostal","year":"2012","journal-title":"J Clin Apheresis"},{"key":"10.1016\/j.jaad.2013.05.002_bib125","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2013.05.002_bib126","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumor necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib127","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1346-8138.2010.00893.x","article-title":"Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab","volume":"37","author":"Kreft","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib128","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1346-8138.2009.00616.x","article-title":"Toxic epidermal necrolysis successfully treated with etanercept","volume":"36","author":"Gubinelli","year":"2009","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib129","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1346-8138.1999.tb02082.x","article-title":"Treatment of severe drug eruptions","volume":"26","author":"Roujeau","year":"1996","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib130","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1365-2133.2009.09585.x","article-title":"Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea and Westminster TEN management protocol","volume":"162","author":"de Sica-Chapman","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib131","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2133.1996.tb01167.x","article-title":"Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis","volume":"135","author":"Goulden","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib132","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1067\/mjd.2002.118557","article-title":"Toxic epidermal necrolysis treated with N-acetylcysteine","volume":"46","author":"Velez","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/931528","article-title":"Cephazolin-induced toxic epidermal necrolysis treated with intravenous immunoglobulin and N-acetylcysteine","volume":"2012","author":"Saavedra","year":"2012","journal-title":"Case Rep Immunol"},{"key":"10.1016\/j.jaad.2013.05.002_bib134","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.002_bib135","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporine A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J Trauma"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213005094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213005094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:28:36Z","timestamp":1759271316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962213005094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":135,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0190962213005094"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2013.05.002","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxic epidermal necrolysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}